Your browser doesn't support javascript.
loading
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroglu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowicz, Andrzej; Losonczy, György; Conev, Nikolay V; Armstrong, Jon; Byrne, Natalie; Shire, Norah; Jiang, Haiyi; Goldman, Jonathan W.
Afiliación
  • Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic address: lpazaresr@seom.org.
  • Dvorkin M; BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia.
  • Chen Y; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA.
  • Reinmuth N; Asklepios Lung Clinic, Munich-Gauting, Germany.
  • Hotta K; Okayama University Hospital, Okayama, Japan.
  • Trukhin D; Odessa National Medical University, Odessa, Ukraine.
  • Statsenko G; Omsk Regional Cancer Center, Omsk, Russia.
  • Hochmair MJ; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus Nord, Vienna, Austria.
  • Özgüroglu M; Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Ji JH; Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
  • Voitko O; Kyiv City Clinical Oncological Centre, Kiev, Ukraine.
  • Poltoratskiy A; Petrov Research Institute of Oncology, St Petersburg, Russia.
  • Ponce S; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
  • Verderame F; AO Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy.
  • Havel L; Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czechia.
  • Bondarenko I; Dnipropetrovsk Medical Academy, Dnipro, Ukraine.
  • Kazarnowicz A; Tuberculosis and Lung Disease Hospital, Olsztyn, Poland.
  • Losonczy G; Semmelweis University, Budapest, Hungary.
  • Conev NV; Clinic of Medical Oncology, UMHAT St Marina, Varna, Bulgaria.
  • Armstrong J; AstraZeneca, Cambridge, UK.
  • Byrne N; AstraZeneca, Cambridge, UK.
  • Shire N; AstraZeneca, Gaithersburg, MD, USA.
  • Jiang H; AstraZeneca, Gaithersburg, MD, USA.
  • Goldman JW; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Lancet ; 394(10212): 1929-1939, 2019 11 23.
Article en En | MEDLINE | ID: mdl-31590988
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Etopósido / Carcinoma Pulmonar de Células Pequeñas / Antineoplásicos Inmunológicos / Neoplasias Pulmonares / Anticuerpos Monoclonales / Antineoplásicos Fitogénicos Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Lancet Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Etopósido / Carcinoma Pulmonar de Células Pequeñas / Antineoplásicos Inmunológicos / Neoplasias Pulmonares / Anticuerpos Monoclonales / Antineoplásicos Fitogénicos Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Lancet Año: 2019 Tipo del documento: Article